To our knowledge, only two studies applied WES to clinical IBC samples [12, 26], but the series were small (respectively 22 patients with advanced HER2+ IBC and 6 patients with hormone receptor-positive (HR+) IBC) and most of patients had been pre-treated. Here, ERBB2 is linked to inflammatory breast carcinoma.